#668of 1,000 in 2025

International Society for Pharmacoepidemiology

Location
Washington, District of Columbia
Founded
1989
297%Three-year growth, FY2022 to FY2025
$3.1MFY2025 revenue
0Employees, FY2025
#22of 29 in District of Columbia

Revenue by fiscal year

FY2022: $787,810 $788K FY22 FY2023: $2,328,719 $2.3M FY23 FY2024: $2,523,335 $2.5M FY24 FY2025: $3,127,773 $3.1M FY25

Where revenue came from, FY2025

Program revenue
$3.1M · 100%
Total revenue on the 990
$3,252,371
Investment income
− $124,598
Revenue we count
$3,127,773

What it does

See Schedule O

Development and management of scientific forums: 1) convene an annual scientific forum (international conference on pharmacoepidemiology & therapeutic risk management - ICPE) where members of the discipline meet to network, present results of methodological investigations and studies in progress, discuss public health policy issues concerning pharmacoepidemiology, therapeutic risk management, and other related fields. 2) Convene regular regional and local meetings on scientific and public policy issues, which currently includes a mid-year conference in conjunction with meetings of the board of directors and scientific program committee; and an annual Asian conference (ACPE) partnered with local scientific and professional societies.
The Societys communications program delivers: 1) a website with significant resources on the expanding science and practice of pharmacoepidemiology, and presents ISPEs goals and objectives to current/prospective members, and the general public; and 2) regular email updates to members on developments in pharmacoepidemiology, or about ISPE.
Publications: 1) The Society provides a members-only subscription to Pharmacoepidemiology and Drug Safety, a leading scientific journal publishing definitive, peer-reviewed papers on the science and practice of pharmacoepidemiology; and 2) a Manuscript Initiative, which funds the development of resource documents focused on pharmacoepidemiology, pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness research, and therapeutic risk management.

Leadership

Mary Beth RitcheyPrincipal officer

EIN 41-1688677 · Full filings on ProPublica

Want to share your story?

We’d love to hear your story of growth.

Share your story